EGI
TGTX icon

EAM Global Investors’s TG Therapeutics TGTX Stock Holding History

EAM Global Investors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-116,293
Closed -$4.59M – 114
2025
Q1 		$4.59M Buy
+116,293
New +$3.91M 1.25% 34
2023
Q1 		– Sell
-108,820
Closed -$1.29M – 185
2022
Q4 		$1.29M Buy
+108,820
New +$790K 0.33% 157
2021
Q2 		– Sell
-28,211
Closed -$1.36M – 211
2021
Q1 		$1.36M Sell
28,211
-3,844
-12% -$185K 0.38% 136
2020
Q4 		$1.67M Sell
32,055
-33,127
-51% -$1.12M 0.45% 114
2020
Q3 		$1.74M Sell
65,182
-30,846
-32% -$710K 0.64% 74
2020
Q2 		$1.87M Buy
+96,028
New +$1.55M 0.84% 48

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM Global Investors's TGTX Position: Q2 2025 in Review

EAM Global Investors sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 116,293 shares — an estimated $4.59M sold.

EAM Global Investors first reported a position in TGTX in Q2 2020 and held it in 6 quarters. The position peaked at $4.59M in Q1 2025. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • EAM Global Investors reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EAM Global Investors sold 116,293 TG Therapeutics shares in Q2 2025, an estimated $4.59M.
  • EAM Global Investors first reported a position in TG Therapeutics in Q2 2020 and held it in 6 quarters.
  • EAM Global Investors's TG Therapeutics position peaked at $4.59M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on EAM Global Investors's 13F filing for Q2 2025, filed 12 Aug 2025.